Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIOT2: Intracavitary Tocilizumab for Malignant Pleural Effusion and Ascites
NCT06016179Phase 1Recruiting
- Sponsor
- Allegheny Singer Research Institute
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tocilizumab in malignant pleural effusion (MPE) and malignant ascites, sponsored by Allegheny Singer Research Institute. Primary endpoints: Successful intra-cavitary administration of tocilizumab at 6 weeks and Adverse Events at 6 weeks. Started Jan 2024; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
malignant pleural effusion (MPE)malignant ascites
Beyond the preview
Go deeper on NCT06016179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016179.